CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a ...

Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations ...

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy ...

Until now. Last week, Eli Lilly and Company announced results of a Phase 2 trial that demonstrated its drug, Lepodisiran, significantly reduced "the production of lipoprotein(a) levels by an ...

Too much LDL or Lp(a) can raise a person's risk of plaque build-up in their arteries, which then increases their risk of heart attacks and strokes. © Sakurra via ...

Firmly established as an icon to British youth, the Londoner discusses his upcoming fourth album, masculinity in the wake of ...

An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high ...

In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the ...

Until now. Last week, Eli Lilly and Company announced results of a Phase 2 trial that demonstrated its drug, Lepodisiran, significantly reduced “the production of lipoprotein(a) levels by an average ...

In particular, the study suggests that hormone therapy may lower levels of lipoprotein(a), a genetic risk factor associated with a higher risk of heart attack and stroke. Their findings were ...

In an exclusive interview with NBC News, President Donald Trump said there were methods that would allow him to seek a third ...

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the blood. The drug, made by Eli Lilly and called lepodisiran, lowered ...